Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

New Agent Shows Potential in Battling Renal Cancer

By BiotechDaily International staff writers
Posted on 27 Feb 2013
Image: The compound TIR-199 holds much promise in the laboratory in fighting renal cancer (Photo courtesy of the University of California, Riverside).
Image: The compound TIR-199 holds much promise in the laboratory in fighting renal cancer (Photo courtesy of the University of California, Riverside).
Chemists have developed a substance in the laboratory that has potential applications in fighting renal cancer.

The compound, called IR-199, targets the proteasome, a cellular complex in renal cancer cells, similar to the way the drug bortezomib, approved by the US Food and Drug Administration, targets and blocks the proteasome in multiple myeloma cells, a cancer that arises in bone marrow.

Dr. Michael Pirrung, a distinguished professor of chemistry at the University of California, Riverside (USA;), reported on the findings on the development of TIR-199 on February 19, 2013, at the 5th International Conference on Drug Discovery and Therapy, held in Dubai (UAE).

Functioning similar to a cellular garbage dump, the proteasome degrades proteins. Agents that suppress the action of proteasomes are called proteasome inhibitors, and have been shown to have activity against a range of cancer cell lines, although with varied results. Bortezomib, for instance, although effective against multiple myeloma, has numerous side effects because cells other than bone marrow cells are affected. “The novel feature of our new proteasome inhibitor, TIR-199, is that it is nearly as potent as bortezomib, but is selective in inhibiting the growth of only renal cancer cell lines,” Dr. Pirrung said. “It’s what makes TIR-199 attractive.”

The TIR-199 project at UC Riverside began approximately four years ago after a multidisciplinary, international group of scientists reported on a class of compounds that act on the proteasome. These compounds are the “syringolin” natural products—such as a compound generated naturally by the wheat-infecting bacterium Pseudomonas syringae. TIR-199 is a synthetic relative of syringolin. “At UCR we began to work on, and completed the synthesis of, two compounds from this class of compounds,” Dr. Pirrung said. “Of the two, TIR-199 showed most promise.”

Dr. Pirrung’s laboraroty first shipped TIR-199 samples to the University of Hawaii, Hilo, where Dr. André Bachmann, an associate professor of pharmaceutical sciences and Dr. Pirrung’s collaborator, researched TIR-199 in assays for how it worked against the proteasome. Dr. Bachmann then tested the compound against a limited number of cancer cell lines that demonstrated that TIR-199 was effective against the cancer cells. However, it still is not known, however, was if TIR-199 was toxic to normal cells.

Encouraged by these results, Dr. Pirrung submitted TIR-199 samples to the National Cancer Institute at the US National Institutes of Health (Bethesda, MD, USA), where the compound was subjected to a stringent 60-cell screening used typically to assess compounds for their effectiveness in fighting 60 types of cancer, including lung, leukemia, colon, brain, breast, ovarian, prostate, and renal cancers.

“We were very excited when the NCI informed us that TIR-199 has excellent potential to be moved to drug development because of its selective activity against renal cancer,” Dr. Pirrung said. “This is good news also because the NCI scientists told us there really are no good drugs out there to fight renal cancer.”

In the next phase, the NCI will evaluate TIR-199 on cells cultured in a hollow fiber that partially imitates the body by providing a three-dimensional (3D) setting. If the test findings are promising, TIR-199 will be assessed on lab mice.

The UCR Office of Technology Commercialization has filed a patent application on TIR-199 and is currently looking for collaborators in industry interested in developing the compound commercially. Several biotechnology companies have already shown interest. “We still have to fine-tune TIR-199 in the lab because some aspects--certain structural elements within it--make it easily metabolized,” Dr. Pirrung said. “But now that we have a good handle on how structural changes in the compound affect anticancer activity and how the parent drug binds to the proteasome, we are pretty confident of making a better version--the second generation--of TIR-199.”

Related Links:

University of California, Riverside



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.